FDA Approves Treatment for Disease That Causes Recurrent Inflammation in Sac Surrounding Heart - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. FDA Approves First Treatment for Disease That Causes Recurrent Inflammation in Sac Surrounding Heart FDA has approved Arcalyst (rilonacept) injection to treat recurrent pericarditis and reduce the risk of recurrence in adults and children 12 years and older.   Recurrent pericarditis is characterized by a remitting-relapsing inflammation (or symptoms that fluctuate in severity) of the pericardium, a thin tissue sac surrounding the heart. Pericarditis often causes chest pain, which can be sharp. This chest pain worsens when patients take a deep breath.   Serious, life-threatening infections have been reported in patients taking Arcalyst. Patients with active or chronic infections should not take the drug. Patients should also avoid live vaccines while taking Arcalyst.   Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA